Lung adenocarcinoma during pregnancy: clinical case and literature review

Bellido, Claudio A.; Barbero, Patricia; Forcén, Laura; Blanco, Marcos; Alonso-Riaño, Marina; Galindo, Alberto

doi:10.1080/14767058.2018.1461830

Cited by 15 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung adenocarcinoma (LUAD), a leading cause of cancer-related mortality, accounts for ∼40% of NSCLCs and has a 5-year survival rate of only 15% [ 2 ]. At present, patients with LUAD are usually diagnosed at the terminal stage or following metastasis due to the lack of effective biomarkers and obvious early symptoms [ 3 , 4 ]. For more than half a century, even with the significant progress and development made in molecular biology, oncology, and medicinal technology, the treatment of LUAD has been and remains ineffective [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

The Effect of lncRNA SNHG3 Overexpression on Lung Adenocarcinoma by Regulating the Expression of miR-890

Kang

Qiu

Zhang

2021

Journal of Healthcare Engineering

View full text Add to dashboard Cite

The lncRNA small nucleolar host gene 3 (SNHG3) was discovered to play an important role in the occurrence and development of lung adenocarcinoma (LUAD). However, the underlying molecular mechanism of SNHG3 in LUAD remains unclear. In the present study, SNHG3 expression levels in LUAD tissues and cell lines were analyzed using reverse transcription-quantitative PCR. The effects of SNHG3 on the proliferation, apoptosis, migration, and invasion of LUAD cells were determined using Cell Counting Kit-8, colony formation, flow cytometry, wound healing, and Transwell chamber assays, respectively. The specific underlying mechanism of SNHG3 in LUAD was investigated using bioinformatics analysis and a dual luciferase reporter assay. The results revealed that SNHG3 expression levels were downregulated in LUAD tissues and cell lines. Functionally, SNHG3 overexpression suppressed the proliferation, migration, and invasion of LUAD cells, while promoting apoptosis. Mechanistically, microRNA- (miR-) 890 was identified as a potential target of SNHG3, and its expression was negatively regulated by SNHG3. Notably, SNHG3 was found to promote LUAD progression by targeting miR-890. In conclusion, the findings of the present study revealed that lncRNA SNHG3 promoted the occurrence and progression of LUAD by regulating miR-890 expression.

show abstract

Section: Introductionmentioning

confidence: 99%

The Effect of lncRNA SNHG3 Overexpression on Lung Adenocarcinoma by Regulating the Expression of miR-890

Kang

Qiu

Zhang

2021

Journal of Healthcare Engineering

View full text Add to dashboard Cite

show abstract

“…Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers, and although its diagnosis during pregnancy is rare (less than 1% of pregnancy-associated cancers) [ 5 ], it is increasing in pregnant women and often occurs at an advanced stage in 98% of cases [ 17 ]. Oncogene mutations are more frequent among cases of NSCLC that occur during pregnancy [ 56 ]. In cases of NSCLC with EGFR activating mutations, the protein kinase inhibitors gefitinib, erlotinib, and osimertinib are standard first-line treatments [ 57 , 58 , 59 ].…”

Section: Resultsmentioning

confidence: 99%

“…In cases of NSCLC with EGFR activating mutations, the protein kinase inhibitors gefitinib, erlotinib, and osimertinib are standard first-line treatments [ 57 , 58 , 59 ]. NSCLC with anaplastic lymphoma kinase (ALK) rearrangement is less frequent than NSCLC with EGFR mutations, and is usually treated with crizotinib or alectinib [ 56 ]. The ESMO clinical practice guidelines recommend the combination of carboplatin and paclitaxel for the treatment of NSCLC during pregnancy, but discourage the use of protein kinase inhibitors given the current lack of data [ 17 ].…”

Section: Resultsmentioning

confidence: 99%

“…In humans, ALK-rearranged NSCLC during pregnancy has been described [ 56 , 142 , 143 ], and one study reported intrauterine growth restriction in one twin of a dichorionic diamniotic pregnancy after intrauterine exposure to erlotinib [ 144 ], but normal development at 12 months. These data should be interpreted with caution given the suspected toxicity of these drugs to trophoblasts.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Cancer during Pregnancy: A Review of Preclinical and Clinical Transplacental Transfer of Anticancer Agents

Benoit

Mir

Vialard

et al. 2021

Cancers

View full text Add to dashboard Cite

The occurrence of cancer during pregnancy is observed in 1 in 1000 pregnancies and is expected to increase given the trend of delaying childbearing. While breast cancer is the most common, the incidence of other cancers, such as cervical, ovarian, and lung cancers as well as hemopathies and melanomas, is also increasing. Thus, cancer occurrence in pregnant women raises questions of management during pregnancy and, especially, assessment of the treatment benefit–risk ratio to ensure optimal management for the mother while ensuring the safety of the fetus. Chemotherapy remains a cornerstone of cancer management. If the use of anticancer agents appears possible during pregnancy, while avoiding the first trimester, the extent of placental transfer of different anticancer agents varies considerably thereafter. Furthermore, the significant physiological pharmacokinetic variations observed in pregnant women may have an impact on the placental transfer of anticancer agents. Given the complexity of predicting placental transfer of anticancer agents, preclinical studies are therefore mandatory. The aim of this review was to provide updated data on in vivo and ex vivo transplacental transfer of anticancer agents used in the management of the most common pregnancy-associated cancers to better manage these highly complex cases.

show abstract

“…In patients with positive driver gene, targeted therapy might be considered a good choice. 28 , 29 Immunotherapy can be assumed as the next treatment option for pregnant woman with negative driver gene. Flint et al 30 analyzed the feasibility of ICI for pregnant woman undergoing ICI by comparing the immunological similarities and differences between pregnancy and cancer.…”

Section: Pregnancymentioning

confidence: 99%

Immune Checkpoint Inhibitors in Special Populations

Shan

2021

Technol Cancer Res Treat

View full text Add to dashboard Cite

Cancer is the second leading cause of death in the worldwide. With the growing burden of cancer, the studies on early diagnosis, treatment and prevention of cancer are rapidly increasing. Recently, many new therapeutic strategies have been discovered, among which immunotherapy has dramatically changed the outlook for cancer treatment. Several clinical trials are underway around the world to produce potential treatments. However, these trials set certain strict joining conditions, so that the clinical data cannot be fully applied in the real world. To help clinical oncologists with treatment decision-making, this review collected recent studies on special populations receiving immunotherapy, including organ transplant patients, pregnant women, pediatric patients, patients with pulmonary tuberculosis, patients with human immunodeficiency virus, and patients with autoimmune diseases and mental illness.

show abstract

Lung adenocarcinoma during pregnancy: clinical case and literature review

Cited by 15 publications

References 15 publications

The Effect of lncRNA SNHG3 Overexpression on Lung Adenocarcinoma by Regulating the Expression of miR-890

The Effect of lncRNA SNHG3 Overexpression on Lung Adenocarcinoma by Regulating the Expression of miR-890

Cancer during Pregnancy: A Review of Preclinical and Clinical Transplacental Transfer of Anticancer Agents

Immune Checkpoint Inhibitors in Special Populations

Contact Info

Product

Resources

About